Treatment strategies for mucocutaneous leishmaniasis

• Main Author: Emilio Palumbo
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2010-01-01
• Series: Journal of Global Infectious Diseases
• Subjects: Cutaneous leishmaniasis; Paromomycin; Pentavalent antimonials; Treatment
• Online Access: http://www.jgid.org/article.asp?issn=0974-777X;year=2010;volume=2;issue=2;spage=147;epage=150;aulast=Palumbo

Mucocutaneous is an infection caused by a single celled parasite transmitted by sand fly bites. There are about 20 species of Leishmania that may cause mucocutaneous leishmaniasis. Some Leishmania species are closely linked to humans and are therefore found in cities (L. tropica) whereas some others are more traditionally associated with animal species and therefore considered zoonoses (L. major). The evidence for optimal treatment of mucocutaneous leishmaniasis is patchy. Although the cutaneous form of the disease is often self-limiting, it does result in significant scarring and can spread to more invasive, mucocutaneous disease. Therefore, treatment may be considered to prevent these complications. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use and adverse effects.